glp 1 agonists with cardiovascular benefit GLP-1 receptor and outcome trials: An update Professor Lars Ryden - 'Are

Retatrutide is often described as 8.9 times native GIP potency, 0.40 times native GLP-1 potency, and 0.34 times native glucagon potency

Can GLP-1 drugs benefit patients who are not obese

The ADA/EASD consensus report 4 highlights the use of DDP-4 inhibitors when intermediate efficacy for glucose lowering is required and where weight management goals would prefer a weight-neutral approach

Loomis, R

Theoretically, its systemic anti-inflammatory and gut-healing properties could be a subject of interest for research into other inflammatory skin conditions like rosacea, eczema, or psoriasis, but this is also speculative and requires formal study.

Now, can you talk a little bit about this scan and this test